Miscellaneous
Dr Roger Hajjar, Mount Sinai Medical Center, Scientific Founder of Celladon talks about progress in clinical trials of an AAV vector expressing SERCA2 delivered by intracoronary injection in patients with severe heart failure. Interview by Nick Lemoine, Editor of Gene Therapy Nature Specialist Journals at the ESGCT and BSGT meeting in Brighton in October 2011.